Percutaneous absorption and metabolism of Irgasan DP300.
D000273:Adipose Tissue / Q000187:drug effects; D000287:Administration, Topical; D000818:Animals; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000032:analysis / Q000378:metabolism*; D001646:Bile / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D002722:Chlorobenzenes / Q000008:administration & dosage / Q000378:metabolism; D002852:Chromatography, Ion Exchange; D002855:Chromatography, Thin Layer; D005243:Feces / Q000032:analysis; D006168:Guinea Pigs; D006801:Humans; D007274:Injections, Intraperitoneal; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D010647:Phenyl Ethers / Q000008:administration & dosage / Q000378:metabolism*; D051381:Rats; D012867:Skin / Q000032:analysis; D012869:Skin Absorption; D012915:Soaps; D013737:Testis / Q000378:metabolism; D014316:Tritium
D000891:Anti-Infective Agents, Local; D002722:Chlorobenzenes; D010647:Phenyl Ethers; D012915:Soaps; D014316:Tritium